Document |
Document Title |
WO/2020/127225A1 |
The present invention relates to 3 -( 1,2,3,6-tetrahydropyridin-2-yI)pyridine glutarate or a pharmaceutically acceptable solvate thereof, to a crystal thereof and to a polymorph of this crystal It further relates to the medicinal use of ...
|
WO/2020/130585A1 |
The present invention relates to a sustained-release injection preparation comprising biodegradable polymer microspheres containing deslorelin as an active ingredient, and a preparation method therefor. The sustained-release microsphere ...
|
WO/2020/128876A1 |
The present invention provides a nutraceutical composition comprising iodine, selenium, vitamin D3 and lycopene as active ingredients and other ingredients in specific proportion for the prevention and treatment of hypothyroidism in the ...
|
WO/2020/132023A1 |
Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfon
yl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-
yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that...
|
WO/2020/118437A1 |
The present invention relates to new compounds and compositions comprising active ingredient derivatives of testosterone, and novel testosterone derivatives, novel testosterone methods, novel testosterone compositions, novel testosterone...
|
WO/2020/122385A1 |
The present invention relates to a composition comprising an elecampane extract for prevention and alleviation or treatment of premenstrual syndrome. In detail, the composition can be advantageously available as a composition for prevent...
|
WO/2020/122373A1 |
The present invention relates to a composition comprising a Glycyrrhiza uralensis extract as an active ingredient for prevention, alleviation, or treatment of late-onset hypogonadism syndrome. The Glycyrrhiza uralensis extract that is an...
|
WO/2020/118564A1 |
Compounds are provided having the structure of Formula (I) : (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein X1, X2, and R1 are as defined herein. Such compounds function as thyr...
|
WO/2020/123827A1 |
The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRα selectivity while maintaining good THRβ agonistic activity, thereby impr...
|
WO/2020/120463A1 |
The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin a...
|
WO/2020/122681A1 |
A composition of the present invention relates to a composition comprising dutasteride, wherein said composition may maintain a constant concentration of dutasteride in blood and continuously release a drug thereof for a long period of t...
|
WO/2020/115500A1 |
Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Al...
|
WO/2020/111652A1 |
The present invention relates to a composition for preventing or alleviating metabolic bone diseases or menopausal symptoms, containing a complex extract of Pueraria Radix and Platycodon grandiflorum as an active ingredient. When the pre...
|
WO/2020/108228A1 |
The present invention belongs to the field of biomedicine, and specifically discloses an exenatide analog. The present invention makes a design for several amino acid structures at the C-terminus of the amino acid sequence of exenatide E...
|
WO/2020/108451A2 |
|
WO/2020/111524A1 |
Salts and crystalline forms of the compound of chemical formula 1, that is, (R)-4-((2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-
1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[puro[3,4
-d]pyrimidine-5,4'-piperidine]-3(2H,4H,...
|
WO/2020/111651A1 |
The present invention relates to a composition for preventing or alleviating metabolic bone disease or menopausal symptoms, the composition including, as an effective ingredient, a complex extract of Schisandra fruit and Platycodon. When...
|
WO/2020/105381A1 |
The present invention provides: a cell device that is capable of maintaining a cell aggregate at a high number density and achieving both a high therapeutic efficacy and a low invasiveness by means of the cell aggregate; a method for man...
|
WO/2020/106084A1 |
The present invention relates to a composition for improvement of female menopausal (climacteric) disorders, comprising as an active ingredient a combination of a red clover extract and a hops extract, more specifically a food compositio...
|
WO/2020/093142A1 |
The present disclosure concerns peptide compounds of formula (I) or (II) and combinations thereof that can be administered orally for promoting endogenous steroid, and particularly testosterone, production: A-Xaa1Xaa2-Xaa3-Xaa4-Xaa5-Xaa6...
|
WO/2020/094698A2 |
The present disclosure provides compositions and methods for treating estrogen-dependent disorders, such as disorders of the female reproductive system, including uterine fibroids and endometriosis, among others. Compounds described here...
|
WO/2020/091265A1 |
The present invention relates to a composition comprising an elderberry extract as an effective component for preventing, treating, or alleviating male climacteric syndrome, wherein the elderberry extract of the present invention increas...
|
WO/2020/092898A1 |
Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.
|
WO/2020/083694A1 |
The present invention concerns a dermatological composition comprising a plant progesterone and at least one plant extract, the plant extract preferably having a soothing, anti-oedematous, decongestant and/or anti-inflammatory effect. Th...
|
WO/2020/084548A1 |
A pharmaceutical mucoadhesive gel composition for delivering therapeutic agents (such as progesterone) by buccal, nasal, vaginal and rectal administration, thereby avoiding the hepatic first-pass metabolism. The gel composition comprises...
|
WO/2020/084435A1 |
The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-meth
ylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical compos...
|
WO/2020/085373A1 |
The present invention provides a novel compound which has activating activity selective for ERβ. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...
|
WO/2020/079079A1 |
The present invention relates to co-crystals comprising levothyroxine and a dicarboxylic acid, preferably L-tartaric acid or oxalic acid, and processes for the preparation thereof. Furthermore, the invention relates to a pharmaceutical c...
|
WO/2020/081726A1 |
This disclosure describes studies undertaken to determine the effectiveness of administration of low dose progesterone monotherapy in alleviating symptoms associated with menopause transition. It is apparent based on initial results that...
|
WO/2020/074707A1 |
The invention relates to corticotropin releasing hormone or a synthetic derivative thereof, for use in the prevention or treatment of adrenal insufficiency in critically ill patients.
|
WO/2020/074926A1 |
The disclosures herein relate to novel compounds of formula (1) : (1) and salts thereof, wherein W, X, Y, Z, m, n, q, R1, R2, R3, R4, R5 and R6 are defined herein, and their use in treating, preventing, ameliorating, controlling or reduc...
|
WO/2020/074958A1 |
Disclosed are methods for treating congenital adrenal hyperplasia or primary aldosteronism in a subject in need thereof, comprising administering a therapeutically effective amount of 2S,4R ketoconazole enantiomer substantially free of t...
|
WO/2020/073974A1 |
Provided herein are novel thyroid hormone receptor (TR) agonists, e. g., having Formula I, II, or III. Also provided are methods of preparing the novel TR agonists and method of using the novel TR agonists for treating diseases or disord...
|
WO/2020/076752A1 |
Studies in female mice lacking ovaries (and thus estrogen), and placed on a high fat diet (60% fat) to induce severe obesity, and then stimulated with a low level of high pressure stress on the heart to induce mild hypertrophy and activa...
|
WO/2020/076051A1 |
The present invention relates to a pharmaceutical composition, a food composition and a food additive for preventing or alleviating symptoms of andropause, all of which contain an extract of Ficus auriculata Lour. as an active ingredient...
|
WO/2020/070017A1 |
This invention relates to novel uses of botulinum neurotoxin in treating a disease or condition associated with lipoedema, in particular uses of botulinum neurotoxin in treating pain associated with lipoedema.
|
WO/2020/073017A1 |
This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate ca...
|
WO/2020/067930A1 |
The invention relates to the field of organic chemistry, and in particular to new compounds that are amides of beta-amino acids of stereoisomers of 3-azabicyclo[2.2.1]heptene-2-carbonitrile of formula (I) or pharmaceutically acceptable s...
|
WO/2020/063407A1 |
The present invention relates to general formulas (I) and (II) an N-aromatic amide compound and a preparation method therefor, a pharmaceutical composition and a pharmaceutical preparation containing the general formulas (I) and (II), an...
|
WO/2020/067832A1 |
The present invention relates to a composition for prevention or treatment of hypercortisolemia, the composition comprising allithiamine, fursultiamine, and benfotiamine, which are all derivatives of thiamine, or a mixed composition ther...
|
WO/2020/059892A1 |
The purpose of the present invention is to provide a novel method for making it possible to efficiently induce/produce endocrine cells from pluripotent stem cells. Insulin-producing cells including cells that are insulin-positive and NKX...
|
WO/2020/058474A1 |
A method of treating exocrine pancreatic insufficiency includes administering to an individual in need thereof (e.g., an individual with cystic fibrosis) an effective amount of an enteral composition having a total protein consisting ess...
|
WO/2020/058322A1 |
The present invention provides glucose sensitive insulin derivatives comprising a macrocycle, a glucose mimetic and human insulin or an analogue thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical ...
|
WO/2020/054795A1 |
[Problem] To provide: an anti-aging agent which is safe even when ingested for a long period and can prevent the progression of aging effectively; and others. [Solution] The anti-aging agent contains nicotinamide mononucleotide as an act...
|
WO/2020/051973A1 |
Application of terra flava usta in preparation of medicaments for preventing and/or treating allergic diseases, mental diseases, metabolic diseases, and endocrine disorder-related diseases; and application of the terra flava usta in prep...
|
WO/2020/051344A1 |
This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant...
|
WO/2020/051260A1 |
This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treatin...
|
WO/2020/050290A1 |
The purpose of the present invention is to provide a medicine which contains a small-molecule compound as an active ingredient, and which can exhibit an activity to ameliorate an obesity-related metabolic disease, e.g., an anti-obesity a...
|
WO/2020/044314A1 |
Pediatric and modified release dosage forms of vitamin D compounds, and methods of making and using the same, are disclosed.
|
WO/2020/045497A1 |
Provided are a simple and minimally invasive testing method and an agent for diagnostic tolerance testing for distinguishing aldosterone-producing adenoma and idiopathic aldosteronism. Provided is the agent for diagnostic tolerance testi...
|